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Abstract: Background  
The European Friedreich's Ataxia Consortium for Translational Studies 
(EFACTS) is a prospective international registry investigating the 
natural history of Friedreich ataxia (FRDA). We report one- and two-year 
longitudinal data to delineate potential outcomes for clinical trials.  
 
Methods  
We enrolled genetically confirmed FRDA patients from eleven European 
study sites. Patients were seen on an annual basis at three visits. Our 
primary endpoint was the Scale for the Assessment and Rating of Ataxia 
(SARA). Secondary outcomes were the Inventory of Non-Ataxia Signs (INAS), 
the Spinocerebellar Ataxia Functional Index (SCAFI), phonemic verbal 
fluency (PVF) and the quality of life measures activities of daily living 
(ADL) and EQ-5D-3L index. Disease progression was analyzed with linear 
mixed effect models. This study is registered with ClinicalTrials.gov, 
number NCT02069509. 
 
Findings  
605 FRDA patients were enrolled between 15-Sep-2010 and 21-Nov-2013. 546 
patients (90%) contributed data with at least one follow-up visit. Annual 
progression rate for SARA was 0·77 points (SE 0·06). Deterioration in 
SARA was associated with a lower age of onset (by -0·02 [0·01] points per 
year) and a lower SARA baseline score (-0·07 [0·01] per baseline-point). 
Patients with more than 353 GAA repeats on the shorter allele had a 
higher SARA progression rate (by 0·09 [0·02] per additional 100 repeats). 
Annual worsening for INAS was 0·10 (0·03), for SCAFI -0·04 (0·01), for 
ADL 0·93 (0·06) and for EQ-5D-3L -0·02 (0·004). PVF performance improved 
by 0·99 [0·14] words per year. 548 or 184 patients would be needed to 
detect a 50% reduction in SARA progression at 80% power in a one-year or 
two-year clinical trial, respectively.  
 
Interpretation  
The EFACTS longitudinal analysis provides suitable outcome measures and 
sample size calculation for upcoming clinical trial designs in FRDA. 
 
Funding  
FP7 Grant from the European Commission (HEALTH-F2-2010- 242193). 
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Summary 
 
Background The European Friedreich’s Ataxia Consortium for Translational Studies 
(EFACTS) is a prospective international registry investigating the natural history of Friedreich 
ataxia (FRDA). Based on our 1 year and 2 year data we aimed to delineate potential 
outcomes for clinical trials.  
 
Methods We enrolled patients with genetically confirmed FRDA from 11 European study 
sites. Patients were seen on an yearly basis at three visits. Our primary endpoint was the 
Scale for the Assessment and Rating of Ataxia (SARA). Secondary outcomes were the 
Inventory of Non-Ataxia Signs (INAS), the Spinocerebellar Ataxia Functional Index (SCAFI), 
phonemic verbal fluency (PVF), and the quality of life measures activities of daily living (ADL) 
and EQ-5D-3L index. Disease progression was analysed with linear mixed effect models. 
This study is registered with ClinicalTrials.gov, number NCT02069509. 
 
Findings 605 FRDA patients were enrolled between 15-Sep-2010 and 21-Nov-2013. 546 
patients (90%) contributed data with at least one follow-up visit. Annual progression rate for 
SARA was 0·77 points (SE 0·06) in the overall cohort. Deterioration in SARA was associated 
with a lower age of onset (by -0·02 [0·01] points per year) and a lower SARA baseline score 
(-0·07 [0·01] per baseline-point). Patients with more than 353 GAA repeats on the shorter 
allele had a higher SARA progression rate (by 0·09 [0·02] per additional 100 repeats). 
Annual worsening for INAS was 0·10 (0·03), for SCAFI -0·04 (0·01), for ADL 0·93 (0·06) and 
for EQ-5D-3L -0·02 (0·004). PVF performance improved by 0·99 [0·14] words per year. 548 
or 184 patients would be needed to detect a 50% reduction in SARA progression at 80% 
power in a one-year or two-year clinical trial, respectively.  
 
Interpretation The EFACTS longitudinal analysis provides suitable outcome measures and 
sample size calculation for upcoming clinical trial designs in FRDA. 
 
Funding FP7 Grant from the European Commission (HEALTH-F2-2010- 242193). 
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Introduction 
Although a rare disorder, Friedreich’s ataxia (FRDA) is the most common hereditary ataxia in 
white people, with an estimated prevalence of 2–4 per 100000 population.1 This recessive 
disease is caused in up to 98%2 of cases by homozygous guanine-adenine-adenine (GAA) 
triplet repeat expansions in the first intron of the FXN gene, encoding the mitochondrial 
protein frataxin. The remaining cases are compound heterozygotes for a GAA repeat 
expansion and a FXN point mutation or deletion.3 GAA repeat expansions suppress 
transcription of the FXN gene, leading to frataxin deficiency. The disease is characterised by 
spinocerebellar ataxia, dysarthria, pyramidal weakness, deep sensory loss, hypertrophic 
cardiomyopathy, skeletal abnormalities, and diabetes mellitus.4 Clinical onset is most 
commonly around puberty, but in a few cases symptoms develop later in adulthood. In its 
typical form, this chronic devastating disease leads to severe disability by early adulthood, 
with substantial functional loss, wheelchair dependence, and loss of quality of life. Affected 
individuals have a reduced life expectancy, with many premature deaths due to 
complications of the cardiomyopathy at about the end of the fourth decade of life.5 
Previous natural history studies in genetically confirmed cases of FRDA, including our 
analysis of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS) 
baseline data, have delineated the clinical characteristics of FRDA and provided estimates of 
progression.6-11 Although different clinical assessments were used in earlier studies, the 
conclusions drawn were that earlier onset and longer GAA repeats were associated with 
increased disease severity and more rapid progression. However, there is no prospective 
longitudinal study of the Scale for the Assessment and Rating of Ataxia (SARA), which - 
based on previous estimated progression rates - seems to be a suitable clinical measure to 
monitor disease progression and of the activities of daily living (ADL) to assess functional 
deterioration.7 
As potential disease-modifying therapies in FRDA are emerging, longitudinal studies are 
urgently needed to identify and validate robust measures of clinical progression to guide the 
design of future clinical trials. To address this necessity and to enable the translation to 
clinical practice, we have analysed prospective longitudinal data from the EFACTS database 
representing 2 years of observation. We assessed disease progression and the predictive 
value of disease-related factors on progression, and estimated sample sizes for 
interventional randomised clinical trials.  
 
Methods 
Study design and participants 
Within the framework of the EFACTS project (www.e-facts.eu), patients with a genetically 
confirmed diagnosis of FRDA were enrolled into a cohort study at 11 European centres 
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(Aachen, Bonn, Marburg, Munich, Tübingen [Germany], Brussels [Belgium], Innsbruck 
[Austria], London [UK], Madrid [Spain], Milan [Italy], and Paris [France]). Genetic testing was 
repeated for all study participants at the Laboratoire de Neurologie Exp rimentale of the 
Université Libre de Bruxelles in Brussels.12 The first patient’s baseline visit was Sep 15, 
2010, and the last patient of this cohort was recruited Nov 29, 2013. The last 2 year follow-up 
visit of this cohort was Jan 11, 2016 and the data were closed for this 2 year data analysis on 
Jan 28, 2016. Further follow-up assessments and recruitment of new patients for EFACTS is 
still ongoing. 
All patients or their authorised surrogates provided written informed consent at enrolment 
into EFACTS. This study was approved by the local ethics committees of each participating 
centre.  
 
Procedures 
Assessments were done at all centres in accordance with the same written natural history 
study protocol. A full description of procedures and data collection can be found in our 
previous baseline data report.7  
 
Outcomes 
Briefly, we used SARA,13 a 40-point scale to quantify ataxia signs, with a higher score 
indicating more severe ataxia, as our primary outcome measure.  
 
Secondary outcome measures were the Inventory of Non-Ataxia Signs (INAS),14 which 
provides a count of non-ataxia signs such as changes in reflexes, other motor, sensory or 
ophthalmological signs; the performance-based Spinocerebellar Ataxia Functional Index 
(SCAFI);15,16 a phonemic verbal fluency (PVF) test to probe executive cognitive 
functioning;17,18 the ADL functional activity scale part of the Friedreich Ataxia Rating Scale 
(FARS);19 and the self-reported quality of life EQ-5D-3L index.20  
For primary and secondary outcomes, patients were assessed at baseline (visit 1 [V1]) and 
yearly for 2 years (visit 2 [V2], visit 3 [V3]). 
 
Statistical analysis  
Data are reported as mean (SD) or frequency, as appropriate. To enable a comparison of the 
responsiveness between outcome measures, we calculated standardised response means 
(SRM)—ie, the mean change in scores from baseline to follow-up divided by the standard 
deviation of change The yearly progression for each outcome was estimated with the linear 
mixed-effect modeling with random effects on intercept and slope (proc MIXED in SAS 
[version 9.4]) restricted-maximum-likelihood method). The time variable was calculated in 
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years—ie, days since the baseline visit divided by 365. We used unstructured covariance 
and adjusted the degrees of freedom by the between and within method. Based on previous 
reports showing differential rates of clinical decline in late-onset FRDA (symptom onset at 
≥25 years of age) compared with typical-onset FRDA (age ≤24 years),4,21 we further 
assessed the progression over time within each disease-onset group. 
In a separate analysis, we tested the effects of demographic and disease-related factors on 
progression rates across the entire cohort. Here, we modeled fixed interaction effects 
between time and sex, age in years at visit, educational level,22 age of symptoms onset, 
baseline scores of the respective outcome measure and number of FXN GAA repeats on 
each allele. Study site and baseline scores were additionally included as main effects. 
Continuous variables were mean centred to facilitate interpretation. To assess the model fit, 
we visually inspected the residual plots and excluded observations of extreme outliers based 
on the restricted likelihood distance. Because of potential bias caused by missing values, we 
reanalysed the data for our primary outcome measure SARA using an imputation method for 
missing observations. Furthermore, we were interested in cutoff values for specific factors 
that would enable selection of patients with a higher disease progression on SARA. We 
depicted the established progression for SARA through individual factors (ie, SARA baseline, 
age in years at visit, age of onset, and GAA repeat length) and tried to identify a cutoff point 
through breakpoint analysis of piece-wise linear regression models (two regression lines; 
proc NLIN in SAS. Last, based on the established progression rate for SARA, we calculated 
sample sizes that would enable the detection of a reduction in progression as assessed with 
SARA in a parallel-group interventional trial of treatments with different efficacies and 
observation periods of 1 year and 2 years.23 
Statistical analyses were done with SAS. All tests were two-sided with a p value of 0.05 set 
as the threshold for significance.  
This study is registered with ClinicalTrials.gov, number NCT02069509. 
 
Role of the funding source 
The funders of the study had no role in study design, data collection, analysis, interpretation, 
or writing of the report. The corresponding author had full access to all the data and had final 
responsibility for the decision to submit for publication. 
 
Results  
611 potentially eligible individuals were screened for inclusion in the EFACTS database. In 
six subjects the diagnosis of FRDA could not be genetically confirmed. Thus, a total of 605 
genetically confirmed FRDA patients were enrolled at baseline (Visit 1, V1). Of these, 506 
(84%) completed the one-year follow-up assessments (V2) and 474 (78%) returned to the 
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two-year follow-up assessments (figure 1). 546 patients (90%) contributed longitudinal data 
with at least one follow-up visit. 
Demographic and clinical characteristics at baseline of included FRDA patients are shown in 
table 1. 505 (83%) patients had typical-onset FRDA and 100 (17%) had late-onset FRDA. 
The age of symptom onset was missing for one typical-onset patient. 15 (2.5%) patients (13 
typical-onset, 2 late-onset) were compound heterozygotes with an expanded GAA repeat on 
one allele and a FXN point mutation on the other allele7. Remaining patients were 
homozygous for expanded GAA repeats in the FXN gene, with the shorter repeat containing 
at least 60 GAA triplets. The genetic data set from the EFACTS laboratory was missing for 
eight typical-onset patients with previous external genetic confirmation of homozygous GAA 
repeat expansion.  
Frequencies of missing data for each outcome and visit can be found in appendix table 1. 
Available data at baseline ranged from 96% to 99% for SCAFI, ADL, INAS, and SARA, while 
less data were available for PVF (60%) and EQ-5D-3L (77%; cf. Reetz et al.4). Longitudinally, 
a high percentage of patients with at least two visits contributed data for SARA (90%), INAS 
(90%), SCAFI (88%) and ADL (89%). Again this number was lower for PVF (60%) and EQ-
5D-3L index (71%). 1 year and 2 year responsiveness of outcome measures (table 2) was 
highest for SARA (SRM: 0·33 and 0·55, respectively) and ADL (0·36 and 0·66), and lowest 
for SCAFI (0·05 and -0·05). 
Mean scores of outcome measures at each visit and estimated yearly progression are 
presented in figure 2 and table 2. For linear mixed-effect modeling observations of extreme 
outliers were excluded (ie, SARA/INAS: n=3, SCAFI: n=21; PVF: n=9; ADL: n=2; EQ5D-3L: 
n=8). However, note that additional analysis for our primary outcome SARA using an 
imputation method for missing observations yielded similar results (appendix) as reported in 
the following. For SARA, progression was 0·77 points per year (SE 0·06) across the entire 
cohort. The rate of progression was slightly higher in late-onset patients (0·86 [0·15]) than for 
typical-onset patients (0·75 [0·07]), but this difference in slopes was not significant (-0·11 
[0·17], 95%-CI: -0·44 to 0·21, p=0·49). Analysis of factors possibly affecting disease 
progression (appendix table 2), where we assessed the effect of age of onset as a 
continuous variable on SARA progression across the entire cohort showed that younger age 
of onset was associated with an annual worsening in SARA (by -0·02 [0·01] points per 
additional year). Also, a lower SARA score at baseline was related to a faster progression 
(by -0·07 [0·01] per additional SARA point). We did not find a continuous linear association 
between SARA progression and GAA repeat length. However, breakpoint analysis of linear 
regression models showed a cutoff for GAA repeat length on the shorter allele at 353 (SE 
117; 95% CI: 123 to 584, p=0·0016; appendix figure 1): Patients with more than 353 repeats 
on the shorter allele had an increasing SARA progression rate with higher repeat length (by 
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0·09 [0·02] per additional 100 repeats, 95%-CI: 0·04 to 0·14). We did not find any cutoff 
values for SARA baseline-scores, age or age of onset related to SARA progression. Finally, 
based on the SARA progression rate, we calculated sample sizes for an interventional, 
placebo-controlled trial with different treatment efficacies (figure 3). For a potential treatment 
efficacy of 50% reduction in SARA progression and 80% statistical power, the required 
sample size for a one-year trial would be 548 (274 per group). The corresponding sample 
size in a two-year observational period would be 184 (92 per group). 
Linear mixed effect modeling showed a significant yearly change for all secondary outcomes. 
Across the entire cohort, yearly progression was 0·10 (0·03) points for INAS, and -0·04 
(0·01) for SCAFI. For both measures yearly worsening was stronger in late-onset FRDA than 
in typical-onset patients (INAS: slope for typical-onset 0·06 [0·03], late-onset: 0·33 [0·07], 
difference by -0·26 [0·08] points, 95%-CI: -0·43 to -0·10, p=0·0013; SCAFI: typical-onset -
0·03 [0·01], late-onset: -0·07 [0·02], difference by 0·04 [0·02], 95%-CI: 0·002 to 0·09, 
p=0·04). ADL scores changed by 0·93 [0·06] points per year in the entire cohort; however, 
typical-onset patients showed a higher progression rate than late-onset patients (typical-
onset 0·98 [0·07], late-onset: 0·64 [0·16], difference by 0·35 [0·17], 95%-CI: 0·01 to 0·68, 
p=0·04). We further found an annual improvement in PVF performance by about one word 
per year (0·99 [0·14]), and annual worsening of the EQ-5D-3L index by -0·02 [0·004] points 
in the entire cohort. There were no significant differences between onset groups (PVF: 
typical-onset 0·90 [0·15], late-onset: 1·39 [0·30], difference by -0·49 [0·34], 95%-CI: -1·16 to 
0·18, p=0·15; EQ5D-3L: typical-onset -0·02 [0·005], late-onset: -0·01 [0·01], difference by -
0·01 [0·01], 95%-CI: -0·03 to 0·01, p=0·20). 
Younger age at disease onset and older age at baseline were related to the yearly worsening 
of INAS (by -0·01 [0·004] and 0·01 [0·003] per additional year, respectively), ADL (-0·04 
[0·01], 0·02 [0·01]) and EQ-5D-3L (0·002 [0·001], 0·002 [0·0004]) as well as less 
improvement in PVF (0·12 [0·02], -0·05 [0·01]) (appendix table 2). For each measure, less 
impairment (or better performances) at baseline were associated with a greater deterioration 
over time (by -0·21 [0·02] per additional INAS point; -0·06 [0·01] per ADL point; by -0·03 
[0·01] per SCAFI point; by -0·19 [0·02] per EQ-5D-3L point; -0·19 [0·02] per word in PVF). 
Less improvement in PVF was observed with higher GAA repeats on the longer allele (by -
0·26 [0·07] per additional 100 repeats. A higher number of GAA repeats on the shorter allele 
predicted worsening that was not significant in ADL (p=0·07) and EQ-5D-3L (p=0·08). Sex 
effects were only found for PVF with female patients showing a greater improvement over 
time (0·74 [0·27] per additional word). A lower educational level was associated with a 
decrease in SCAFI performance over time (0·02 [0·01] per ISCED unit). 
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Discussion  
The results from EFACTS provide evidence for measurable phenotypic change over 2 years 
in FRDA patients. The main results of the study are that SARA is a suitable clinical rating 
scale to detect deterioration of ataxia symptoms over time; ADL is an appropriate measure to 
monitor changes in daily self-care activities; younger age at disease onset is a major 
predictor for faster disease progression; and sample sizes for interventional trials can now be 
provided. 
The main objective of EFACTS has been to define potential outcome measures for disease-
modifying trials in FRDA. Our primary clinical outcome measure SARA showed good 
responsiveness, in particular over 2 years (0·55), and a significant annual progression rate 
(0·77 points/year) across the entire FRDA cohort. Although the progression rate was slightly 
higher in late-onset FRDA (0·86 points/year) than in the typical-onset group (0·75 
points/year), late-onset patients also showed higher variability of SARA change over time 
and the difference between onset-groups was not significant. Lower SARA baseline-scores 
in late-onset patients (table 2) might further account for the marginally increased progression 
rate, as we could show that less impairment at baseline predicts faster deterioration in ataxia 
symptoms over time. Further analysis confirmed that earlier age of disease onset is 
associated with a stronger worsening in SARA, which is in agreement with our baseline 
report and other previous studies.6-8,10,24,25 Our analysis showed a differential predictive value 
of the GAA repeat length of the shorter allele for SARA progression, as it was evident only in 
patients having an expansion of more than 353 repeats. This corresponds to previous work 
showing that GAA repeats interfere with in vitro transcription in a length-dependent manner,26 
and might explain to some extent findings of a previous longitudinal study,27 in which the link 
between SARA progression and GAA repeat expansion could not be substantiated. 
Generally, the length of the shorter allele is acknowledged to be more predictive for earlier 
disease onset and severity of disease5 than the length of the larger allele.21,28 
Several different ataxia-rating scales have been used in previous studies. In previous natural 
history studies in FRDA, the International Cooperative Ataxia Rating Scale (ICARS)5,6,10,11, 
FARS8,9,11,29, or SARA,5,7,27,30 have been used. ICARS and particularly FARS have been 
shown to be appropriate markers for the assessment of disease progression in FRDA in 
longitudinal studies of 1 year11, 2 years8,9, or even up to 7 years10. However, the compact 
nature of SARA and its ability to capture disease progression in FRDA favours its clinical 
use. 
A major achievement for future trials, the EFACTS data will now enable the calculation of 
sample sizes for interventional trials. For example, for a placebo-controlled interventional 
trial, 548 FRDA patients would be needed to detect a 50% reduction in SARA progression at 
80% power over 1 year. The required sample size for a clinical trial can be reduced to 184 
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patients in a 2-year trial. Our calculated sample size corresponds well compared with recent 
published sample-sizes from the American/Australian cohort31, although our 2-year data 
differ, which might be due to different methodological statistics, design, and lower retention 
rates of the American/Australian cohort. Our findings show that 2 years of observation are 
needed for a feasible clinical trial. A prespecified selection, e.g. lower baseline score, 
younger age of onset, and genetic aspects, might further decrease the number of patients 
needed. 
Using INAS to assess non-ataxic signs in FRDA, we found that the number of non-ataxic 
features of the disease marginally increases over time, though effects were larger in late-
onset patients. This supports the notion that phenotypical changes in late-onset FRDA may 
evolve differentially and emphasises the consideration of non-ataxia signs particularly in this 
population. Again, both lower INAS baseline-scores and younger age of disease onset had 
an effect on INAS deterioration, suggesting a more progressive appearance of symptoms 
with an earlier disease course. The functional composite index SCAFI showed a small 
responsiveness over time, but deterioration was significantly higher in late-onset FRDA. As 
shown for each outcome, a better performance (or less impairment) at baseline was related 
to stronger worsening over time, which is reasonable given the potential range of further 
progression in less impaired patients. Floor effects in SCAFI performances, however, are 
more likely4, occurring particularly in patients with typical-onset, who are unable to perform all 
SCAFI tasks because of physical limitations (e.g. 8 m-walk). The neurocognitive measure 
PVF showed a somewhat surprising annual improvement about one word per year in all 
groups. This improvement might have resulted from an increased familiarity with the task in 
follow-up measurements, for which we also had a higher number of missing data 
compromising interpretation of results. Currently, SCAFI and INAS are appropriate for use as 
secondary outcome measures to detect changes in functional performances and to provide 
valuable information on non-ataxia signs particularly in late-onset FRDA. 
An important goal of our study was to quantify how FRDA progressively interferes with daily 
activities and impacts patients’ quality of life7. The ADL measure of functional status 
demonstrated high responsiveness (SRM 0·66 after 2 years) and yearly progression (0·93) 
across the entire FRDA cohort, more marked in the typical-onset group (SRM 0·72 and 
yearly progression 0·98), but also apparent in late-onset FRDA (SRM 0·39 and yearly 
progression 0·64). By contrast, the self-rated quality of life measure EQ-5D-3L showed a 
rather small decline, likely reflecting the good cognitive and emotional status of FRDA 
patients18 compared to other neurodegenerative diseases such as Huntington’s disease. In 
particular the strong responsiveness of ADL – even superior than for SARA – indicate the 
necessity of functional status and quality of life assessments in addition to motor function in 
clinical trials.  
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The 2-year follow-up of the EFACTS cohort provided clinically relevant data, but this is a 
short time for a slowly progressive disease like FRDA. Additionally, although we tried to 
handle missing data with statistical procedures, dropout rates increased over time and varied 
substantially among measures. Fewer data were missing for SARA and ADL than for the 
other outcome measures, whereas more data were missing for other measures like PVF and 
might have weakened conclusions we could draw. Another limitation is that our study did not 
include quantitative neurophysiological or neuroimaging data. 
In conclusion, our results of the 2 year analysis of the EFACTS cohort allowed substantiation 
of the suitability of the SARA and ADL as robust outcome measures for future therapeutic 
trials, which should be designed with an observational period of at least 2 years. 
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Panel: Research in context 
 
Evidence before this study 
We searched PubMed for articles on Friedreich ataxia published between Jan 1, 1996 
(identification of the genetic cause), and April 15, 2016, using the search terms “Friedreich 
ataxia AND progression”, and “Friedreich ataxia AND natural history” resulting in the 
identification of 11 peer-reviewed studies in English. Three studies were retrospective 
surveys, one of these focusing only on late-onset Friedreich ataxia patients. Three were of 
prospective, cross-sectional nature, including our baseline analysis. Three of the five 
longitudinal studies followed patients for 1 year or 2 years, or both. The two remaining were 
long-term follow-up studies, one following patients for up to 7 years using the International 
Cooperative Ataxia Rating Scale, the other one concentrating on cardiac outcome measures 
for up to 22 years. Overall, these studies show the impact of earlier disease onset and its 
association with a faster disease progression. However, usage of clinical rating scales is 
heterogeneous. To date, there is no prospective study with a comparable large cohort in 
FRDA showing changes in ataxia and non-ataxia symptoms as well as functional measures 
over 2 years. 
Added value of this study 
This European, multicentre, longitudinal study of Friedreich ataxia provides data for yearly 
change in clinical measures based on observations at three timepoints over 2 years in the 
worldwide largest cohort of 605 genetically confirmed Friedreich ataxia patients enrolled 
across 11 sites. We corroborate our baseline cross-sectional data, emphasizing the 
advantages of the Scale for the Assessment and Rating of Ataxia, assessing major clinical 
deterioration, and of the activities of daily living to measure functional decline in Friedreich 
ataxia with age of onset being a strong predictor for faster disease progression. Power 
calculations show that a 2 years of observation are needed for a feasible clinical trial.  
  
Implications of all the available evidence 
Our data have important implications for future research and in particular the design of 
upcoming clinical trials in FRDA patients as they provide suitable clinical measures and 
power calculations. Overall, the available evidence now delivers the long hampering pieces, 
large-scale studies of progression and sample size requirements. 
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Legends 
Figure 1 –  Flow-chart of FRDA patients 
The flow-chart presents the number of patients at baseline (V1), at one-year follow-up (V2) 
and two-year follow-up (V3) with drop-out rates including the respective reasons.  
 
Figure 2 –  Progression of primary and secondary outcome measures for the total 
cohort and by onset group 
Data are mean with 95% confidence interval at baseline (V1), visits V2 and V3. Dashed line 
indicates significant annual progression over time at p<0·05 estimated based on linear mixed 
effect modeling (please see Table 2). 
 
Figure 3 –  Sample size estimates 
Required sample sizes to detect differences in SARA progression at p<0·05 as a function of 
treatment effectiveness for an observational period of one and two years, statistical power of 
(A) 80% and (B) 90%. 
 
Table 1: FRDA cohort characteristics at baseline (V1) 
 Total cohort 
(n=605; 100%) 
Typical-onset FRDA 
(n=505; 83%) 
Late-onset FRDA 
(n=100; 17%) 
Female (%) 325 (54%) 266 (53%) 59 (59%) 
Age at study entry in years  37·9 (13·9) 30·2 (11·8) 51·2 (9·7) 
Age at onset in years * 15·5 (10·4) 11·7 (5·1) 34·8 (8·7) 
Disease duration  in years* 18·2 (10·3) 18·5 (10·6) 16·4 (8·1) 
Disability stage
+
 4·8 (1·5) 4·9 (1·4) 3·9 (1·3) 
Wheelchair-bound (%) 292 (48%) 280 (55%) 12 (12%) 
Education (ISCED)
†
 3·3 (1·3) 3·3 (1·3) 3·3 (1·3) 
Number of FXN GAA repeats
¶
:    
Shorter allele 1 590 (270) 654 (239) 273 (177) 
Longer allele 2 903 (211) 934 (179) 753 (282) 
Inter-visit time (years): V1 to V2 1·1 (0·2) 1·1 (0·2) 1·1 (0·1) 
 V1 to V3 2·1 (0·2) 2·1 (0·2) 2·1 (0·2) 
Date are mean (standard deviation) or n (%); ISCED, International Standard Classification of Education (1997). *Data 
are missing for one typical-onset patient; 
†
data missing for three typical-onset patients; 
¶
data missing for eight typical-
onset patients. 
+
Disability stage was recorded on a range from 1 (no functional handicap but signs at examination) to 6 
(wheelchairbound) and 7 (confined to bed). 
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Table 2: Outcome measures at each visit and annual progression rates  
 Baseline  
(V1) 
One-year follow-up  
(V2) 
Two-year follow-up  
(V3) 
Annual progression rate*  
 N Mean (SD) N Mean (SD) SRM N Mean (SD) SRM Estimate (SE) 95% CI p value 
SARA total score 600 21·9 (9·6) 502 22·5 (9·5) 0·33 471 23·2 (9·1) 0·55 0·77 (0·06) 0·65 to 0·89 <0·0001 
Typical-Onset FRDA 500 23·3 (9·4)  414 24·1 (9·2) 0·33 393 24·6 (8·9) 0·53 0·75 (0·07) 0·62 to 0·88 <0·0001 
Late-onset FRDA 100 14·7 (7·4) 88 14·9 (7·2) 0·29 78 16·2 (6·8) 0·69 0·86 (0·15) 0·57 to 1·16 <0·0001 
INAS count 603 5·0 (1·9) 500 5·1 (1·9) 0·08 468 5·2 (1·8) 0·17 0·10 (0·03) 0·04 to 0·16 0·0007 
Typical-Onset FRDA 503 5·2 (1·9) 412 5·3 (1·8) 0·04 390 5·3 (1·7) 0·10 0·06 (0·03) -0·004 to 0·13 0·0676 
Late-onset FRDA
#
 100 3·9 (1·6) 88 4·3 (1·9) 0·27 78 4·6 (1·9) 0·50 0·33 (0·07) 0·18 to 0·47 <0·0001 
SCAFI z-score 579 -0·43 (1·7) 492 -0·40 (1·7) 0·05 452 -0·48 (1·6) -0·05 -0·04 (0·01) -0·05 to -0·02 <0·0001 
Typical-Onset FRDA 485 -0·57 (1·8) 407 -0·54 (1·7) 0·07 377 -0·59 (1·7) -0·02 -0·03 (0·01) -0·05 to -0·01 0·0004 
Late-onset FRDA
#
 94 0·33 (0·7) 85 0·25 (1·0) -0·13 75 0·08 (1·0) -0·29 -0·07 (0·02) -0·11 to -0·04 <0·0001 
PVF, no of words 359 13·9 (6·7) 359 15·0 (6·7) 0·19 345 15·8 (6·8) 0·43 0·99 (0·14) 0·72 to 1·26 <0·0001 
Typical-Onset FRDA 288 13·0 (6·2) 287 14·1 (6·3) 0·18 279 15·1 (6·5) 0·36 0·90 (0·15) 0·60 to 1·20 <0·0001 
Late-onset FRDA 71 17·8 (7·3) 72 18·8 (6·8) 0·20 66 19·0 (7·4) 0·69 1·39 (0·30) 0·79 to 1·98 <0·0001 
ADL total score 597 14·6 (7·8) 502 15·6 (7·8) 0·36 472 16·5 (7·9) 0·66 0·93 (0·06) 0·80 to 1·05 <0·0001 
Typical-Onset FRDA 498 15·5 (7·9) 414 16·7 (7·9) 0·39 394 17·5 (7·9) 0·72 0·98 (0·07) 0·85 to 1·12 <0·0001 
Late-onset FRDA
# 
99 10·2 (5·3) 88 10·6 (4·9) 0·25 78 11·4 (5·4) 0·39 0·64 (0·16) 0·33 to 0·94 <0·0001 
EQ-5D-3L index 466 0·59 (0·2) 405 0·57 (0·2) -0·06 381 0·56 (0·2) -0·22 -0·02 (0·004) -0·03 to -0·01 <0·0001 
Typical-Onset FRDA 374 0·57 (0·2) 322 0·55 (0·2) -0·07 309 0·53 (0·2) -0·24 -0·02 (0·004) -0·03 to -0·01 <0·0001 
Late-onset FRDA 92 0·67 (0·2) 83 0·68 (0·1) 0·002 72 0·66 (0·1) -0·16 -0·01 (0·009) -0·02 to 0·01 0·4914 
*Slope of time effect using linear mixed effects modeling (see methods for further details); 
#
significant differences in slopes between onset groups at p<0.05; SD, 
standard deviation; SRM, standardized response mean (i.e., mean change compared to baseline divided by the standard deviation of the mean change); SE, standard 
error; CI, confidence interval; SARA, Scale for the Assessment and Rating of Ataxia; INAS, Inventory of Non-Ataxia Symptoms; SCAFI, Spinocerebellar Ataxia 
Functional Index; PVF, phonemic verbal fluency; no, number; ADL, activities of daily living. Note, that higher values for SARA, INAS and ADL indicate stronger 
impairment (vice versa for SCAFI, PVF, and EQ-5D-3L index). 
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Figure 1 –  Flow-chart of enrolled FRDA patients in EFACTS  
 
Abbr.: N=number, V=visit 
Missed Visit (V2) 
N = 99 
 
Termination N = 22 (3.6% of V1) 
Deceased: N = 3 
Withdrawal of consent: N = 1 
Logistical reasons: N = 9 
Loss of contact: N = 9 
 
Baseline (V1) 
N = 605  
One year follow-up (V2) 
N = 506 (84% of V1) 
 
Two year follow-up (V3) 
N = 474 (78% of V1) 
Return to V3 
N = 40 
N = 506 
N = 434 
N = 99 
Missed Visit (V3) 
N = 72 
 
Termination N = 10 (1.7% of V1) 
Deceased: N = 2 
Unwilling to come: N = 4 
Too affected to come: N = 1 
Logistical reasons: N = 3 
 
N = 72 
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Figure 2 – Progression of primary and secondary outcome measures for the total 
cohort and by onset group  
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Figure 3 – Sample size estimates for SARA 
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Appendix 
Appendix Table 1: Missing data and longitudinal data contribution 
 Baseline  
(V1, N=605: 
505 typical, 100 late FRDA) 
One-year follow-up  
(V2, N=506:  
418 typical, 88 late FRDA) 
Two-year follow-up  
(V3, N=474:  
396 typical, 78 late FRDA) 
Total number of patients with 
recorded data 
 N Missing  (%) N Missing (%) N Missing (%) at 3 visits (%) 2 visits (%) 
SARA 600 5 (0.8) 502 4 (0.8) 471 3 (0.6) 425 (70.2) 544 (89.9) 
Typical-onset FRDA 500 5 (1.0) 414 4 (1.0) 393 3 (0.8) 349 (69.1) 454 (89.9) 
Late-onset FRDA 100 0 (0.0) 88 0 (0.0) 78 0 (0.0) 76 (76.0) 90 (90.0) 
INAS 603 2 (0.3) 500 6 (1.2) 468 6 (1.3) 424 (70.1) 544 (89.9) 
Typical-onset FRDA 503 2 (0.4) 412 6 (1.4) 390 6 (1.5) 348 (68.9) 454 (89.9) 
Late-onset FRDA 100 0 (0.0) 88 0 (0.0) 78 0 (0.0) 76 (76.0) 90 (90.0) 
SCAFI 579 26 (4.3) 492 14 (2.8) 452 22 (4.6) 387 (64.0) 534 (88.3) 
Typical-onset FRDA 485 20 (4.0) 407 11 (2.6) 377 19 (4.8) 320 (63.4) 446 (88.3) 
Late-onset FRDA 94 6 (6.0) 85 3 (3.4) 75 3 (3.8) 67 (67.0) 88 (88.0) 
Verbal fluency 359 246 (40.7) 359 147 (29.1) 345 129 (27.2) 201 (33.2) 363 (60.0) 
Typical-onset FRDA 288 217 (43.0) 287 131 (31.3) 279 117 (29.5) 154 (30.5) 291 (57.6) 
Late-onset FRDA 71 29 (29.0) 72 16 (18.2) 66 12 (15.4) 47 (47.0) 72 (72.0) 
ADL 597 8 (1.3) 502 4 (0.8) 472 2 (0.4) 426 (70.4) 541 (89.4) 
Typical-onset FRDA 498 7 (1.4) 414 4 (1.0) 394 2 (0.5) 351 (69.5) 451 (89.3) 
Late-onset FRDA 99 1 (1.0) 88 0 (0.0) 78 0 (0.0) 75 (75.0) 90 (90.0) 
EQ-5D-3L index 466 139 (23.0) 405 101 (20.0) 381 93 (19.6) 296 (48.9) 428 (70.7) 
Typical-onset FRDA 374 131 (25.9) 322 96 (23.0) 309 87 (22.0) 231 (45.7) 343 (67.9) 
Late-onset FRDA 92 8 (8.0) 83 5 (5.7) 72 6 (7.7) 65 (65.0) 85 (85.0) 
Missing data evaluated as a percentage of the patients who contributed data at the respective visit. SARA, Scale for the Assessment and Rating of Ataxia; INAS, 
Inventory of Non-Ataxia Symptoms; SCAFI, Spinocerebellar Ataxia Functional Index; ADL, activities of daily living. 
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Appendix Table 2: Linear mixed effect modeling results   
 Estimate SE t-value p-value 
     
SARA     
Site: Aachen -0.1437 0.2699 -0.53 0.5947 
Bonn 0.2352 0.3125 0.75 0.4521 
Brussels -0.1034 0.2588 -0.40 0.6896 
Innsbruck -0.1061 0.2468 -0.43 0.6675 
London 0.04660 0.2121 0.22 0.8261 
Madrid 0.07261 0.2260 0.32 0.7481 
Marburg 0.6219 0.4853 1.28 0.2006 
Milano -0.00925 0.2116 -0.04 0.9651 
Munich -0.1221 0.2504 -0.49 0.6261 
Paris -0.00999 0.2403 -0.04 0.9669 
Time  0.7889 0.1771 4.45 <.0001 
SARA baseline 1.0001 0.004401 227.26 <.0001 
Time*SARA baseline -0.07235 0.009603 -7.53 <.0001 
Time*Sex -0.1329 0.1194 -1.11 0.2659 
Time*Age 0.009578 0.008224 1.16 0.2445 
Time*Education 0.009629 0.04691 0.21 0.8374 
Time*Age of onset -0.02271 0.01096 -2.07 0.0386 
Time*GAA repeats (allele 1) 0.000532 0.000327 1.63 0.1037 
Time*GAA repeats (allele 2) 0.000213 0.000340 0.63 0.5315 
INAS     
Site: Aachen 0.1310 0.1529 0.86 0.3917 
Bonn -0.05071 0.1740 -0.29 0.7708 
Brussels 0.1316 0.1450 0.91 0.3644 
Innsbruck 0.09730 0.1376 0.71 0.4799 
London 0.01765 0.1190 0.15 0.8822 
Madrid 0.1219 0.1272 0.96 0.3380 
Marburg 0.02883 0.2332 0.12 0.9017 
Milano 0.2177 0.1204 1.81 0.0712 
Munich -0.00848 0.1382 -0.06 0.9511 
Paris 0.2192 0.1355 1.62 0.1063 
Time  0.1835 0.08374 2.19 0.0287 
INAS baseline 0.9706 0.01333 72.81 <.0001 
Time*INAS baseline -0.2149 0.01924 -11.17 <.0001 
Time*Sex 0.02261 0.05553 0.41 0.6840 
Time*Age 0.01226 0.003195 3.84 0.0001 
Time*Education -0.03055 0.02198 -1.39 0.1649 
Time*Age of onset -0.00942 0.004475 -2.10 0.0356 
Time*GAA repeats (allele 1) 0.000165 0.000145 1.14 0.2561 
Time*GAA repeats (allele 2) 0.000172 0.000159 1.08 0.2788 
SCAFI  
Site: Aachen 0.005187 0.03435 0.15 0.8800 
Bonn 0.03406 0.03920 0.87 0.3853 
Brussels 0.006505 0.03280 0.20 0.8429 
Innsbruck 0.02561 0.03133 0.82 0.4141 
London 0.02254 0.02711 0.83 0.4061 
Madrid 0.02089 0.02877 0.73 0.4682 
Marburg -0.01681 0.05186 -0.32 0.7459 
Milano -0.00876 0.02750 -0.32 0.7501 
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Munich 0.02623 0.03146 0.83 0.4048 
Paris 0.03965 0.03120 1.27 0.2043 
Time  -0.09254 0.02649 -3.49 0.0005 
SCAFI baseline 0.9983 0.003603 277.12 <.0001 
Time*SCAFI baseline -0.02763 0.007201 -3.84 0.0001 
Time*Sex -0.01023 0.01782 -0.57 0.5662 
Time*Age 0.000874 0.000982 0.89 0.3738 
Time*Education 0.01990 0.006934 2.87 0.0042 
Time*Age of onset -0.00107 0.001415 -0.75 0.4509 
Time*GAA repeats (allele 1) 0.000050 0.000047 1.06 0.2873 
Time*GAA repeats (allele 2) -0.00003 0.000051 -0.67 0.5031 
PVF  
Site: Aachen 0.1222 0.5639 0.22 0.8286 
Bonn -0.9578 0.6448 -1.49 0.1384 
Brussels 0.02582 0.5243 0.05 0.9608 
Innsbruck -0.1674 0.5163 -0.32 0.7459 
London -0.09892 0.5223 -0.19 0.8499 
Madrid 0.3050 0.4544 0.67 0.5026 
Marburg 0.3244 0.8077 0.40 0.6882 
Milano 0.5232 0.4484 1.17 0.2441 
Munich -0.04181 0.4954 -0.08 0.9328 
Paris 0.4254 0.4926 0.86 0.3885 
Time  0.07540 0.4250 0.18 0.8593 
PhVF baseline 0.9651 0.01652 58.44 <.0001 
Time* PhVF baseline -0.1901 0.02343 -8.12 <.0001 
Time*Sex 0.7375 0.2651 2.78 0.0056 
Time*Age -0.04733 0.01498 -3.16 0.0017 
Time*Education 0.1167 0.1114 1.05 0.2954 
Time*Age of onset 0.1188 0.02312 5.14 <.0001 
Time*GAA repeats (allele 1) 0.001246 0.000737 1.69 0.0915 
Time*GAA repeats (allele 2) -0.00255 0.000745 -3.42 0.0007 
ADL     
Site: Aachen 0.005906 0.2763 0.02 0.9830 
Bonn 0.1933 0.3247 0.60 0.5519 
Brussels -0.09212 0.2651 -0.35 0.7284 
Innsbruck -0.1408 0.2521 -0.56 0.5768 
London -0.07548 0.2176 -0.35 0.7288 
Madrid -0.00917 0.2326 -0.04 0.9686 
Marburg 0.1591 0.4245 0.37 0.7080 
Milano -0.1973 0.2171 -0.91 0.3636 
Munich -0.2344 0.2531 -0.93 0.3548 
Paris 0.04660 0.2477 0.19 0.8508 
Time  0.8241 0.1945 4.24 <.0001 
ADL baseline 0.9944 0.005602 177.52 <.0001 
Time*ADL baseline -0.05703 0.01266 -4.50 <.0001 
Time*Sex 0.06162 0.1309 0.47 0.6379 
Time*Age 0.01848 0.008954 2.06 0.0393 
Time*Education 0.01122 0.05133 0.22 0.8270 
Time*Age of onset -0.03540 0.01191 -2.97 0.0030 
Time*GAA repeats (allele 1) 0.000623 0.000346 1.80 0.0719 
Time*GAA repeats (allele 2) 0.000265 0.000373 0.71 0.4774 
EQ-5D-3L index 
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Site: Aachen -0.00127 0.01966 -0.06 0.9483 
Bonn -0.00008 0.01927 -0.00 0.9968 
Brussels -0.01696 0.01761 -0.96 0.3360 
Innsbruck -0.01258 0.01529 -0.82 0.4110 
London -0.01119 0.01360 -0.82 0.4109 
Madrid -0.00826 0.01491 -0.55 0.5801 
Marburg -0.00597 0.02712 -0.22 0.8257 
Milano -0.00998 0.01314 -0.76 0.4478 
Munich 0.000896 0.01525 0.06 0.9532 
Paris -0.01727 0.01551 -1.11 0.2662 
Time  -0.02122 0.01202 -1.77 0.0779 
EQ5D baseline 0.9671 0.01528 63.31 <.0001 
Time*EQ5D baseline -0.1921 0.02382 -8.07 <.0001 
Time*Sex 0.004516 0.007352 0.61 0.5392 
Time*Age -0.00196 0.000460 -4.26 <.0001 
Time*Education 0.001506 0.003126 0.48 0.6302 
Time*Age of onset 0.002390 0.000587 4.08 <.0001 
Time*GAA repeats (allele 1) -0.00003 0.000019 -1.74 0.0827 
Time*GAA repeats (allele 2) -0.00003 0.000021 -1.47 0.1419 
     
Reference site: Tuebingen; Time, Age and Age of onset in years. * indicates interaction term; SE, 
standard error. SARA, Scale for the Assessment and Rating of Ataxia; INAS, Inventory of Non-Ataxia 
Symptoms; SCAFI, Spinocerebellar Ataxia Functional Index; PVF, phonetic verbal fluency; ADL, 
activities of daily living. 
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Appendix Table 3: Estimates of the fixed effects from multiple imputation 
analysis for SARA 
 Estimate SE t-value p-value 
     
Time  0.840887 0.183204 4.59 0.0001 
SARA baseline 1.000202 0.004773 209.57 <.0001 
Time*SARA baseline -0.069850 0.010000 -6.99 <.0001 
Time*Sex -0.124561 0.123513 -1.01 0.3226 
Time*Age 0.006411 0.008480 0.76 0.4566 
Time*Education -0.006862 0.048094 -0.14 0.8877 
Time*Age of onset -0.020539 0.011365 -1.81 0.0825 
Time*GAA repeats (allele 1) 0.000509 0.000359 1.42 0.1732 
Time*GAA repeats (allele 2) 0.000248 0.000372 0.67 0.5132 
SE, standard error. To address potential bias caused by missing values we reanalyzed the model for our 
primary outcome SARA using an imputation method for missing observations. We used the potential 
predictive variables of our initial model for the imputation model (mcmc). After imputation of observations, 
we applied our mixed model to the imputed datasets and combined the estimates according to Rubin’s 
rule. The results were very similar to the results reported in appendix table 2 without an imputation for 
missing observations. 
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Appendix Figure 1 –  SARA progression rate as a function of GAA repeat length on the shorter allele 
 
Breakpoint analysis of piece-wise linear regression models (NLIN procedure in SAS). Significant cut-off value for SARA progression was identified for 
GAA repeat length on the shorter allele at 353 (SE 117; 95%-CI: 123 to 584, p=0·0016): In patients with more than 353 repeats on the shorter allele, 
SARA progression rate increased by 0·09 [0·02] per additional 100 repeats (95%-CI: 0·04 to 0·14), while in patients with less than 353 repeats a 
negative, but none-significant association between GAA repeat length and SARA progression was found (-0·08 [0·09] per additional 100 repeats, 95%-
CI: -0·27 to 0·10). 
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